<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04824079</url>
  </required_header>
  <id_info>
    <org_study_id>MEDO-007-20002</org_study_id>
    <nct_id>NCT04824079</nct_id>
  </id_info>
  <brief_title>Keynatinib in Treated Patients With NSCLC and Brain Metastases</brief_title>
  <official_title>Study of Keynatinib in Patients With Advanced Non-small Cell Lung Cancer With Brain Metastasis or Progression of Brain Metastasis After Treatment With EGFR Inhibitor(s)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medolution Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medolution Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of Keynatinib capsules in&#xD;
      patients with advanced non-small cell lung cancer (NSCLC) with brain metastasis or&#xD;
      progression of brain metastasis after treatment with EGFR inhibitors. As well as, to evaluate&#xD;
      the penetration rate of Keynatinib in the Blood-Brain Barrier (BBB) and its PK&#xD;
      characteristics, and the relationship between exposure levels with efficacy and safety.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, non-randomized, open, single-arm, phase IIa trial investigating the&#xD;
      security and effectiveness of Keynatinib in patients with advanced non-small cell lung cancer&#xD;
      (NSCLC) with brain metastasis or progression of brain metastasis after treatment with EGFR&#xD;
      inhibitors.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 21, 2020</start_date>
  <completion_date type="Anticipated">July 22, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 22, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>From start of treatment to time of progression (in CNS or non-CNS disease) , intolerable toxicity, withdrawal of informed consent or death, whichever occurs first，assessed up to 2 years.</time_frame>
    <description>The proportion of subjects whose optimal efficacy observed from the beginning of administration is CR or PR.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Non-Small Cell Lung Cancer With EGFR Mutation</condition>
  <condition>Brain Metastases</condition>
  <arm_group>
    <arm_group_label>Keynatinib treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects shall be treated with Keynatinib twice a day (once every 12±3 hours), 20 mg each time, fasting within 2 hours before and 1 hour after taking the drug, and taking warm water when taking the drug. Every 21 days is a treatment cycle .</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Keynatinib</intervention_name>
    <description>The recommended dose is 20 mg Keynatinib twice a day until disease progression， unacceptable toxicity death occurs or withdraw from the study, whichever occurs first.</description>
    <arm_group_label>Keynatinib treatment group</arm_group_label>
    <other_name>TL007</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Unlimited gender, age ≥ 18 years；&#xD;
&#xD;
          2. Histologically or cytologically documented locally advanced, metastatic NSCLC&#xD;
             (including L858R and/or Exon19 del mutation positive). The EGFR mutation assessed by&#xD;
             local laboratory/or central laboratory via tissue/cytology or in plasma;&#xD;
&#xD;
          3. Subjects should have the following conditions: a. (Cohort 1) Progression on any of the&#xD;
             first or second generation EGFR inhibitors (gefitinib, erlotinib, afatinib, etc.).B.&#xD;
             (Cohort 2) Progression on any third generation EGFR inhibitor (oxitinib, etc.), prior&#xD;
             or non-prior treatment with any first or second generation EGFR inhibitor;&#xD;
&#xD;
          4. The peripheral lesions did not progress after EGFR inhibitor treatment, but the&#xD;
             occurrence of brain metastasis or progression of brain metastasis was confirmed by&#xD;
             magnetic resonance imaging (MRI);&#xD;
&#xD;
          5. As determined by the investigator, no final surgical resection or radiotherapy is&#xD;
             expected for all lesions;&#xD;
&#xD;
          6. Stable condition for at least 2 weeks prior to study medication without any&#xD;
             corticosteroid or anticonvulsant therapy;&#xD;
&#xD;
          7. The status score of Eastern Cooperative Oncology Group (ECOG) is 0 to 1 points, and&#xD;
             there was no deterioration during the first 2 weeks of enrollment;&#xD;
&#xD;
          8. Estimated survival time &gt; 3 months；&#xD;
&#xD;
          9. Sufficient bone marrow, liver, kidney and blood coagulation function；&#xD;
&#xD;
         10. Subjects must be willing to use barrier contraception；&#xD;
&#xD;
         11. Ability to provide informed consent, complete all study assessments and have complete&#xD;
             medical record.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Have previously received chemotherapy, immunotherapy or any other systemic antitumor&#xD;
             therapies within 4 weeks before the first administration; Have previously received&#xD;
             EGFR-TKI within 5× half-life before the first administration; Have received oral&#xD;
             fluorouracil and other small-molecule targeted drugs (whichever is longer) within 2&#xD;
             weeks or 5× half-life before enrollment; Within 2 weeks before enrollment, subjects&#xD;
             had received palliative radiotherapy for non-target lesions for symptom relief, and&#xD;
             traditional Chinese medicine (including Chinese patent medicine) for tumor indication;&#xD;
&#xD;
          2. Have received whole brain radiation therapy;&#xD;
&#xD;
          3. Only leptomeningeal metastasis are present;&#xD;
&#xD;
          4. Historical intracranial hemorrhage not related to the tumor;&#xD;
&#xD;
          5. Major organ surgery (excluding needle biopsy) or significant trauma have been&#xD;
             performed within 4 weeks prior to enrollment;&#xD;
&#xD;
          6. The drug or food with strong inhibition or induction of cytochrome P450 (CYP)&#xD;
             isoenzyme CYP3A4 could not be stopped. The drug or food with strong inhibition or&#xD;
             induction of cytochrome P450 (CYP) isoenzyme CYP3A4 had been used within 7 days before&#xD;
             enrollment;&#xD;
&#xD;
          7. Any unresolved toxicities from prior therapy greater than CTCAE 5.0 grade 1 at the&#xD;
             time of enrollment with the exception of alopecia;&#xD;
&#xD;
          8. Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to&#xD;
             swallow the tablet or previous significant bowel resection that would preclude&#xD;
             adequate absorption of Keynatinib;&#xD;
&#xD;
          9. Past medical history of ILD, drug-induced ILD, radiation pneumonitis which required&#xD;
             steroid treatment, or CT scan at baseline revealed the presence of idiopathic&#xD;
             pulmonary fibrosis; Uncontrolled large pleural effusion or pericardial effusion;&#xD;
             Active tuberculosis;&#xD;
&#xD;
         10. Any evidence of severe or uncontrolled systemic diseases, including uncontrolled&#xD;
             hypertension and active bleeding diatheses or active infection including hepatitis B,&#xD;
             hepatitis C and HIV;&#xD;
&#xD;
         11. Have a history of severe cardiovascular disease (NYHA cardiac function grade III or&#xD;
             IV);&#xD;
&#xD;
         12. Other primary malignancies (except cured basal cell carcinoma of the skin and&#xD;
             carcinoma in situ of the cervix) within 5 years;&#xD;
&#xD;
         13. Allergic to the active ingredient or excipient of Keynatinib;&#xD;
&#xD;
         14. Pregnant or lactating women.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Cancer Hospital, Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yuankai Shi, PhD</last_name>
      <phone>+86(010)-87788293</phone>
      <email>syuankaipumc@126.com</email>
    </contact>
    <investigator>
      <last_name>Yuankai Shi, phD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shengyu Zhou, phD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fujian Cancer Hospital</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350014</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wu Zhuang, phD</last_name>
      <phone>+8613809500871</phone>
      <email>Zhuangwu2008@126.com</email>
    </contact>
    <investigator>
      <last_name>Wu Zhuang, phD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henan Cancer Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Huijuan Wu, MD</last_name>
      <phone>+8613838528387</phone>
      <email>13838528387@163.com</email>
    </contact>
    <investigator>
      <last_name>Huijuan Wu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yanqiu Zhao, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hunan Cancer Hospital</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410013</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianhua Chen, MD</last_name>
      <phone>+8613807488036</phone>
      <email>cjh_1000@163.com</email>
    </contact>
    <investigator>
      <last_name>Jianhua Chen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shandong Cancer Hospital</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qisen Guo, phD</last_name>
      <phone>+8613869199681</phone>
      <email>guoqs369@163.com</email>
    </contact>
    <investigator>
      <last_name>Qisen Guo, phD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 23, 2021</study_first_submitted>
  <study_first_submitted_qc>March 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 1, 2021</study_first_posted>
  <last_update_submitted>March 26, 2021</last_update_submitted>
  <last_update_submitted_qc>March 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

